Our work on IL4R mutations in PMBCL has been published in the Blood! This work, which was led by Elena Viganò, establishes IL4R mutations as novel driver alterations and provides a strong preclinical rationale for therapeutic targeting of JAK-STAT signaling in PMBCL.